187 related articles for article (PubMed ID: 34638749)
1. Upregulation of the APOBEC3 Family Is Associated with a Poor Prognosis and Influences Treatment Response to Raf Inhibitors in Low Grade Glioma.
Luo C; Wang S; Liao W; Zhang S; Xu N; Xie W; Zhang Y
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638749
[TBL] [Abstract][Full Text] [Related]
2. The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead.
Granadillo RodrÃguez M; Flath B; Chelico L
Open Biol; 2020 Dec; 10(12):200188. PubMed ID: 33292100
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs regulate APOBEC gene expression.
Cao W; Wu W
Histol Histopathol; 2018 Feb; 33(2):117-120. PubMed ID: 28604942
[TBL] [Abstract][Full Text] [Related]
4. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis.
Gao J; Choudhry H; Cao W
Cancer Sci; 2018 Aug; 109(8):2375-2382. PubMed ID: 29856501
[TBL] [Abstract][Full Text] [Related]
6. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
7. APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinoma.
Ma J; Yang X; Zhang J; Antonoff MB; Wu Q; Ji H
Transl Lung Cancer Res; 2023 Mar; 12(3):580-593. PubMed ID: 37057114
[TBL] [Abstract][Full Text] [Related]
8. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
10. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
[TBL] [Abstract][Full Text] [Related]
12. Understanding the regulation of APOBEC3 expression: Current evidence and much to learn.
Covino DA; Gauzzi MC; Fantuzzi L
J Leukoc Biol; 2018 Mar; 103(3):433-444. PubMed ID: 29345375
[TBL] [Abstract][Full Text] [Related]
13. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?
Warren CJ; Santiago ML; Pyeon D
Annu Rev Virol; 2022 Sep; 9(1):375-395. PubMed ID: 35671565
[TBL] [Abstract][Full Text] [Related]
15. CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.
Wang Z; Zhang J; Zhang H; Dai Z; Liang X; Li S; Peng R; Zhang X; Liu F; Liu Z; Yang K; Cheng Q
Front Cell Dev Biol; 2022; 10():740822. PubMed ID: 35252165
[TBL] [Abstract][Full Text] [Related]
16. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of an APOBEC3 deletion polymorphism for glioma patients in Taiwan.
Chen CH; Wei KC; Liao WC; Lin YY; Chen HC; Feng LY; Liu CH; Huang CY; Chen KT; Wu CS; Chang YS; Yu JS; Chang IY
J Neurosurg; 2023 May; 138(5):1325-1337. PubMed ID: 36152319
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
19. High expression of PD-1 ligands is associated with
Boichard A; Tsigelny IF; Kurzrock R
Oncoimmunology; 2017; 6(3):e1284719. PubMed ID: 28405512
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
Cho SY; Kim S; Kim G; Singh P; Kim DW
Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
